Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Equity Ratio (2022 - 2025)

NewAmsterdam Pharma's Equity Ratio history spans 4 years, with the latest figure at 0.89 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 1.4% year-over-year to 0.89; the TTM value through Dec 2025 reached 0.89, up 1.4%, while the annual FY2025 figure was 0.89, 1.4% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.89 at NewAmsterdam Pharma, down from 0.93 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.96 in Q2 2025 and bottomed at 0.83 in Q4 2023.
  • The 4-year median for Equity Ratio is 0.88 (2024), against an average of 0.89.
  • The largest annual shift saw Equity Ratio dropped 8.84% in 2023 before it increased 12.67% in 2025.
  • A 4-year view of Equity Ratio shows it stood at 0.91 in 2022, then dropped by 8.84% to 0.83 in 2023, then rose by 5.44% to 0.88 in 2024, then grew by 1.4% to 0.89 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Equity Ratio are 0.89 (Q4 2025), 0.93 (Q3 2025), and 0.96 (Q2 2025).